AKESO(HK:09926) Xin Lang Cai Jing·2025-09-08 07:43Group 1 - Citic Lyon maintains "outperform" rating for Kangfang Biotech with a target price of HKD 177, citing excellent treatment performance from the global Phase III clinical study of Ivoris monoclonal antibody [1] - Goldman Sachs maintains "buy" rating for Meituan with a target price of HKD 144, expecting continued leadership in local services as the instant retail market expands [1] - Jianyin International maintains "outperform" rating for BYD, lowering the target price to HKD 115.7 due to a stock split, while highlighting the company's strong supply chain capabilities [1] Group 2 - Dongfang Caifu maintains "accumulate" rating for Pop Mart, noting strong performance in H1 2025 and potential for growth through IP exploration and global store expansion [2] - Goldman Sachs maintains "buy" rating for Ping An Insurance, raising the H-share target price to HKD 61, anticipating profit margin advantages from recent product repricing [3] - Goldman Sachs upgrades Luoyang Molybdenum to "buy" with a target price increase to HKD 10.8, driven by a 38% increase in regular profit due to rising copper and rare metal prices [4] Group 3 - Jefferies maintains "buy" rating for MicroPort with a target price increase to HKD 35, citing strong visibility in order growth and manageable competition in the domestic market [4] - Citic Securities maintains "buy" rating for Li Auto with a target price of HKD 151, expecting quarterly improvements in automotive business due to sales channel adjustments and new model launches [5] - CMB International upgrades UBTECH to "buy" with a target price increase to HKD 140, driven by strong orders for humanoid robots and rapid capacity expansion [6]